SCHEMBL5579690

SCHEMBL5579690

Oc1ccc(-c2nc3cc(OCc4ccccc4)ccc3[nH]2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.59
PRMT5 O14744 10/20 0.57
PTGES O14684 1/20 0.55
ALOX5 P09917 1/20 0.55
LTC4S Q16873 1/20 0.55
DHODH Q02127 3/20 0.54
LMNA P02545 2/20 0.51
CYP1A2 P05177 1/20 0.51
PTGS1 P23219 1/20 0.51
SLC6A2 P23975 1/20 0.51
CYP2C19 P33261 1/20 0.51
PTGS2 P35354 1/20 0.51
SLC6A3 Q01959 1/20 0.51
HIF1A Q16665 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
SCD O00767 1/20 0.51
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31289493 0.84 CHEK2 (0.61) CHEK2PRMT5PTGESALOX5LTC4S
SCHEMBL15455871 0.83 CHEK2 (0.70) CHEK2PRMT5DHODHKDM4EALDH1A1
SCHEMBL12470982 0.83 PRMT5 (0.70) CHEK2PRMT5PTGESALOX5LTC4S
SCHEMBL19432719 0.82 KDM4E (0.55) CHEK2PRMT5DHODHKDM4ENPC1
SCHEMBL9306624 0.81 HPSE (0.52) CHEK2SCDKDM4ENPC1ALDH1A1
SCHEMBL484162 0.81 CHEK2 (0.57) CHEK2PRMT5PTGESALOX5LTC4S
SCHEMBL15245146 0.80 DGAT1 (0.58) CHEK2PRMT5PTGESALOX5LTC4S
SCHEMBL4470392 0.78 NPC1 (0.52) ALOX5LMNACYP1A2KDM4ENPC1
SCHEMBL2131853 0.78 XDH (0.55) ALOX5CYP1A2KDM4ENPC1ALDH1A1
SCHEMBL9529962 0.78 CYP3A4 (0.54) ALOX5DHODHCYP1A2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed
EP-1341768-A1 THERAPEUTIC BENZIMIDAZOLE COMPOUNDS AstraZeneca AB (SE) 2003-09-10 EP disclosed
WO-2002046168-A1 THERAPEUTIC BENZIMIDAZOLE COMPOUNDS ASTRAZENECA AB (SE) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004713-A1 Therapeutic benimidazole compounds ESR2, ESRRA, ESRRB CHEK2 3644/4885PRMT5 3509/4885PTGES 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.